Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.
An article from
Dive Brief
Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.
Published July 6, 2026
Getty Images
Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small…
While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.
Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune…
A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.
Biopharma sales trended upward in the first quarter of this year as eight of the industry’s top-25 companies achieved…
Biotech megarounds rebounded in the first half of 2026, with 40 companies raising $100M+, up from 33 in the same period last year.
Venture capital is already having a record year
